How Immunotherapy Works: Retraining the Immune System in Type 1 Diabetes

In Type 1 diabetes, the body's immune system—designed to protect against infections—mistakenly identifies the insulin-producing beta cells in the pancreas as a threat and attacks them. Over time, this autoimmune attack destroys these cells, leading to insufficient insulin production and lifelong dependence on insulin therapy.

Scientists have identified several hallmarks of this autoimmune process. The disease occurs in genetically predisposed individuals, and involves autoreactive T lymphocytes—immune cells that specifically target the body's own tissues. Patients typically develop islet cell autoantibodies, which are markers of immune attack against the pancreas. Environmental factors, such as certain viral infections, may also trigger the disease, though the precise links remain unclear.

Rather than simply managing blood sugar levels as in traditional diabetes care, immunotherapies take a different approach: they work to reprogram the immune system itself. These treatments are designed to block the killer immune cells responsible for destroying beta cells, slowing or stopping the autoimmune attack before more insulin-producing capacity is lost.

Teplizumab, which received FDA approval, targets T cells and delays the progression to Type 1 diabetes in at-risk individuals. This represents the first regulatory approval of an immunotherapy specifically designed to slow the autoimmune destruction of beta cells. However, it is important to understand that teplizumab delays onset—it is not a cure for Type 1 diabetes.

Researchers are pursuing several immunotherapy strategies beyond T cell-blocking approaches. One area of focus involves regulatory T cells (Tregs)—a specialized subset of immune cells that naturally suppress immune activation. Scientists are developing therapies that harness Tregs to restore immune balance and prevent the body from attacking its own insulin-producing cells.

Other clinical trials have explored more aggressive immune reprogramming, such as using chemotherapy and bone marrow stem cell transplantation to reset the immune system entirely. Islet transplantation combined with targeted immunotherapy also represents an emerging strategy, though it requires careful management of immune suppression to prevent rejection of transplanted tissue while minimizing long-term side effects.

Developing more effective immunotherapies depends on a detailed understanding of how and why the immune system attacks beta cells in Type 1 diabetes. Recent advances in high-dimensional, high-throughput technologies for studying genes and proteins have significantly improved our knowledge of the immune mechanisms driving the disease, particularly the critical role of T cells.

Researchers are also working to develop better ways to monitor beta-cell mass and function during treatment. This information is essential for determining which immunotherapies work best at different stages of the disease—from early-stage disease detection through established Type 1 diabetes. International guidelines now emphasize screening for risk, monitoring early-stage disease, and testing interventions designed to delay progression and preserve beta-cell function.

Origin: YouTube / Diabetes UK (Video report). Evidence: Video report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.